UNSPSC 51332826: Propiomazine

This classification denotes an antipsychotic agent with the molecular formula C20H24N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 242Z0PM79Y, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)phenothiazin-2-yl)- but generally known as propiomazine, which bears US NIH Compound Identifier 4940. European Medicines Agency schedules Propiomazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10110MIG.

UNSPSC 51332826 Propiomazine is a Commodity code that in practice covers state and local procurement of pharmaceutical products and related medical supply systems to support public health initiatives, community health programs, and pharmacy benefit operations. Recent solicitations show state and local governments acquiring naloxone and drug deactivation systems for emergency response, generic pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and direct-to-manufacturer prescription fulfillment capabilities to optimize pharmacy benefit program operations. The issuing bodies span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating state and local jurisdictions. Work ranges from straightforward annual unit purchases of controlled substances and OTC items with quarterly delivery schedules to complex pharmacy benefit program restructuring that eliminates intermediaries and establishes direct vendor relationships with state agencies and self-insured health plans.

Geographic activity centers on Florida, Texas, and Minnesota, with broader multistate reach through cooperative purchasing vehicles. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, under a two-year initial term with one-year renewal option and potential FEMA funding. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, requiring vendors to supply through three authorized wholesalers with a two-year contract term effective July 1, 2026. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to solicit vendor capabilities for direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations. All three opportunities require E-Verify compliance, drug-free workplace certification, and comprehensive insurance coverage; the MMCAP solicitation emphasizes cGMP and Drug Supply Chain Security Act compliance with performance penalties for reporting and onboarding failures.